VRT752271 |
Katalog-Nr.GC17031 |
VRT752271 (BVD-523; VRT752271) ist ein potenter, oral aktiver, hochselektiver, ATP-kompetitiver und reversibler kovalenter Inhibitor von ERK1/2-Kinasen mit einem IC50 von <0,3 nM gegen ERK2. VRT752271 (BVD-523; VRT752271) hemmt die phosphorylierte ERK2 (pERK) und die nachgeschaltete Kinase RSK (pRSK) in einer A375-Melanom-Zelllinie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 869886-67-9
Sample solution is provided at 25 µL, 10mM.
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line[1][2].
In the pharmacokinetic study, the sensitivity and specificity of the assay are found to be sufficient for accurately characterizing the plasma pharmacokinetics of Ulixertinib (VRT752271) in Balb/C mice[2].
References:
[1]. Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801.
[2]. Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5;125:140-4.
Average Rating: 5
(Based on Reviews and 8 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *